Zura Bio Limited (ZURA)
$4.41+4.26%Close
SELLRECOVERY · day 2
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $419M
- Beta
- -0.04
- P/E (TTM)
- -3.90
- Short % float
- 25.91%
- Days to cover
- 4.8
- SI change
- +0.3%
- 1W
- +5.76%
- 1M
- -10.55%
- vs SPY 1W
- +5.89%
- vs SPY 1M
- -13.05%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 10
- VALUE
- 5
- GROWTH
- 39
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-33.0%
REV YoY-
ROE-55.0%
EPS YoY-
ROA-40.2%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-3.90
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B2.84
P/FCF-
EV/EBITDA-2.49
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO12.90
ND/EBITDA-
BETA-0.04
Company news
FAQ
- What is LOPJLB’s current signal on ZURA?
- LOPJLB’s latest quantitative signal on Zura Bio Limited (ZURA) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is ZURA in?
- Zura Bio Limited (ZURA) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Zura Bio Limited (ZURA) do?
- Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoc…